CD3/CD19 neg allogeneic BMT(National Institute of Allergy & Infectious Diseases)

The purpose of this study is to determine whether bilateral orthotopic lung transplantation (BOLT) followed by cadaveric partially-matched CD3+/CD19+ depleted bone marrow transplant (BMT) is safe and effective for individuals aged 10 through 45 years with the diagnosis of primary immunodeficiency (PID) and end-stage lung disease.
The enrollment goal: 8 participants who receive both BOLT and BMT.